Morgan Stanley analysts said the reduction was driven by concerns around Chinese demand for Tesla products.Autosread more
Alphabet Inc's Google said Tuesday that keeping phones up to date and secure was in "everyone's best interests," shortly after the U.S. temporarily eased some trade...Technologyread more
Home Depot on Tuesday reported fiscal first-quarter earnings that beat analysts expectations, despite a damp start to the spring in much of the U.S.Retailread more
Indian billionaire investor Rakesh Jhunjhunwala says he's very upbeat about his country's growth potential after the country underwent a massive banking crisis and the rollout...Asia Economyread more
There's more pain ahead for the U.S. and China amid their bilateral trade dispute, according to one expert.China Politicsread more
Kohl's also for the first time in two years missed same-store sales expectations, with CEO Michelle Gass saying the year "started off slower than we'd like."Retailread more
Semiconductor stocks were sliding again on Monday as concerns over trade flared up again. Six experts weigh in on what this means for the U.S. stock market.Trading Nationread more
You know there's an underlying problem when investment firms start to cut exposure to a particular asset class.Commentaryread more
While Trump's lawyers had argued that the committee's subpoena did not have a legitimate legislative purpose — and was therefore invalid — Mehta took a broader view.Politicsread more
The issue of corporate debt has surfaced as companies continue to use the low rates the Fed has provided to lever up their balance sheets.The Fedread more
(Compares with analyst estimates)
April 30 (Reuters) - Pfizer Inc beat Wall Street estimates for quarterly profit and tweaked its earnings forecast for the year on Tuesday, as it reported rising sales of cancer drug Ibrance and pneumonia vaccine Prevnar, pushing shares in the drugmaker higher.
The company pushed its 2019 adjusted earnings per share forecast marginally higher to $2.83 to $2.93 per share, from a prior estimate of $2.82 to $2.92. Analysts had expected $2.89 per share, according to IBES data from Refinitiv.
Pfizer's blockbuster drug Ibrance raked in sales of $1.13 billion, up 21.4 percent from a year earlier, and ahead of analysts' estimates of $1.12 billion.
Prevnar brought in revenue of $1.49 billion, beating an average analyst estimate of $1.39 billion. Excluding special items, the company earned 85 cents per share, beating analysts' estimate of 75 cents.
Shares in the company rose around 1.5 percent in trading before the bell.
The largest U.S. drugmaker has announced plans to streamline operations since new chief executive Albert Bourla took office at the start of the year with a mandate to push growth and reduce bureaucracy.
To counter the threat of generic competition to Lyrica, one of its biggest drugs, Pfizer has been investing in cancer treatments and gene therapies, and expects to gain approval for a new heart drug, touted as a potential blockbuster, later this year.
The company said net income rose to $3.88 billion, or 68 cents per share, in the first quarter, from $3.56 billion, or 59 cents per share, a year earlier.
Revenue rose 1.6 percent to $13.12 billion, ahead of estimates of $12.99 billion. (Reporting by Tamara Mathias in Bengaluru Editing by Saumyadeb Chakrabarty and Patrick Graham)